Biomarkers of human papillomavirus (HPV)-driven head and neck cancer in Latin America and Europe study: Study design and HPV DNA/p16INK4a status

HEADLAcE Study Group

doi:10.1002/hed.26912

Biomarkers of human papillomavirus (HPV)-driven head and neck cancer in Latin America and Europe study: Study design and HPV DNA/p16^INK4a status

HEADLAcE Study Group

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Background: Human papillomavirus (HPV)-driven head/neck squamous cell carcinomas (HNSCC) prevalence varies globally. We evaluated HPV DNA and p16^INK4a in formalin fixed paraffin embedded (FFPE) HNSCC from Argentina, Brazil, Colombia, and Peru. Methods: HPV was genotyped by PCR-hybridization. All HPV DNA positive and some HPV DNA negative cases underwent p16^INK4a immunohistochemistry. Results: HPV DNA was detected in 32.8%, 11.1%, and 17.8% of oropharyngeal (OPC), oral cavity (OCC) and laryngeal (LC) cancers, respectively. OPC HPV prevalence was higher in Colombia (94.7%), and Argentina (42.6%) compared to Brazil (10.6%) and Peru (0.0%). HPV-16 was the most detected. Other HPVs were found in LC. Higher rates of p16^INK4a positivity were observed among HPV positive OPC/OCC cases compared to LC cases. Conclusions: Our results support a role for HPV-16 in a subset of HNSCC, corroborate the heterogeneity observed in samples from different countries, and contribute additional etiological and biomarkers information in tumors of significant impact worldwide.

Original language	English
Pages (from-to)	122-133
Number of pages	12
Journal	Head and Neck
Volume	44
Issue number	1
DOIs	https://doi.org/10.1002/hed.26912
State	Published - Jan 2022

Bibliographical note

Funding Information:
The authors alone are responsible for the views expressed in this article, and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer /World Health Organization. This work was supported by the São Paulo Research Foundation (FAPESP) (Grant No. 2017/04020‐7 to LLV); Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (Grant No. 306326/2015‐9 to LLV and 303431/2018‐0 to LS); Merck Sharp and Dohme (Investigator Initiated Studies IISP # 56004 to LLV); Fondo Nacional de Desarollo Científico, Tecnológico y de Innovación Tecnológica (Fondecyt) (096‐2017‐FONDECYT to CAC); Italian Ministry of Health (with Ricerca Corrente and 5x1000 funds to SC, Marta Tagliabue); Instituto de Salud Carlos III (ISCIII) through AESI 2017 (Grant No. AC17CIII/00003 to MP) and within the EU‐LAC Health framework. The authors are particularly grateful to Laura Leguina (Pathology Service, Hospital de Oncologia Maria Curie), Victoria Cachau, Maria Alejandra Avagnina, Andrea Paes de Lima (Pathology Department, Hospital de Clinicas General San Martín) and María Luisa Paparella (Faculty of Odontology, Universidad de Buenos Aires), Buenos Aires, Argentina for their support and commitment in sample recruitment. We also acknowledge the collaboration of Prof. Evandro Sobroza de Mello and Allane dos Santos Ferreira from the Department of Pathology of Faculdade de Medicina, Universidade de São Paulo, at ICESP.

Funding Information:
The authors alone are responsible for the views expressed in this article, and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer /World Health Organization. This work was supported by the São Paulo Research Foundation (FAPESP) (Grant No. 2017/04020-7 to LLV); Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (Grant No. 306326/2015-9 to LLV and 303431/2018-0 to LS); Merck Sharp and Dohme (Investigator Initiated Studies IISP # 56004 to LLV); Fondo Nacional de Desarollo Científico, Tecnológico y de Innovación Tecnológica (Fondecyt) (096-2017-FONDECYT to CAC); Italian Ministry of Health (with Ricerca Corrente and 5x1000 funds to SC, Marta Tagliabue); Instituto de Salud Carlos III (ISCIII) through AESI 2017 (Grant No. AC17CIII/00003 to MP) and within the EU-LAC Health framework. The authors are particularly grateful to Laura Leguina (Pathology Service, Hospital de Oncologia Maria Curie), Victoria Cachau, Maria Alejandra Avagnina, Andrea Paes de Lima (Pathology Department, Hospital de Clinicas General San Martín) and María Luisa Paparella (Faculty of Odontology, Universidad de Buenos Aires), Buenos Aires, Argentina for their support and commitment in sample recruitment. We also acknowledge the collaboration of Prof. Evandro Sobroza de Mello and Allane dos Santos Ferreira from the Department of Pathology of Faculdade de Medicina, Universidade de São Paulo, at ICESP.

Funding Information:
Conselho Nacional de Desenvolvimento Científico e Tecnológico, Grant/Award Numbers: 303431/2018‐0, 306326/2015‐9; Fondo Nacional de Desarrollo Científico y Tecnológico, Grant/Award Number: 096‐2017; Fundação de Amparo à Pesquisa do Estado de São Paulo, Grant/Award Number: 2017/04020‐7; Instituto de Salud Carlos III, Grant/Award Number: AC17CIII/00003; Italian Ministry of Health; Merck Sharp and Dohme, Grant/Award Number: IISP#56004 Funding information

Publisher Copyright:
© 2021 Wiley Periodicals LLC.

Keywords

head and neck cancer
human papillomavirus
multinational study
prevalence
risk factors

Access to Document

10.1002/hed.26912

Cite this

@article{4c0048879d444d4886b3f7157137cbd0,

title = "Biomarkers of human papillomavirus (HPV)-driven head and neck cancer in Latin America and Europe study: Study design and HPV DNA/p16INK4a status",

abstract = "Background: Human papillomavirus (HPV)-driven head/neck squamous cell carcinomas (HNSCC) prevalence varies globally. We evaluated HPV DNA and p16INK4a in formalin fixed paraffin embedded (FFPE) HNSCC from Argentina, Brazil, Colombia, and Peru. Methods: HPV was genotyped by PCR-hybridization. All HPV DNA positive and some HPV DNA negative cases underwent p16INK4a immunohistochemistry. Results: HPV DNA was detected in 32.8%, 11.1%, and 17.8% of oropharyngeal (OPC), oral cavity (OCC) and laryngeal (LC) cancers, respectively. OPC HPV prevalence was higher in Colombia (94.7%), and Argentina (42.6%) compared to Brazil (10.6%) and Peru (0.0%). HPV-16 was the most detected. Other HPVs were found in LC. Higher rates of p16INK4a positivity were observed among HPV positive OPC/OCC cases compared to LC cases. Conclusions: Our results support a role for HPV-16 in a subset of HNSCC, corroborate the heterogeneity observed in samples from different countries, and contribute additional etiological and biomarkers information in tumors of significant impact worldwide.",

keywords = "head and neck cancer, human papillomavirus, multinational study, prevalence, risk factors",

author = "{HEADLAcE Study Group} and Laura Sichero and Marta Tagliabue and Giana Mota and Silvaneide Ferreira and Nunes, {Rafaella A.L.} and Casta{\~n}eda, {Carlos Arturo} and Miluska Castillo and Correa, {Rita Mariel} and Sandra Perdomo and Rodr{\'i}guez-Urrego, {Paula A.} and Matos, {Leandro Luongo} and Ansarin Mohssen and Tarik Gheit and Massimo Tommasino and Susanna Chiocca and Villa, {Luisa Lina}",

note = "Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC.",

year = "2022",

month = jan,

doi = "10.1002/hed.26912",

language = "Ingl{\'e}s",

volume = "44",

pages = "122--133",

journal = "Head and Neck Surgery",

issn = "1043-3074",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Biomarkers of human papillomavirus (HPV)-driven head and neck cancer in Latin America and Europe study

T2 - Study design and HPV DNA/p16INK4a status

AU - HEADLAcE Study Group

AU - Sichero, Laura

AU - Tagliabue, Marta

AU - Mota, Giana

AU - Ferreira, Silvaneide

AU - Nunes, Rafaella A.L.

AU - Castañeda, Carlos Arturo

AU - Castillo, Miluska

AU - Correa, Rita Mariel

AU - Perdomo, Sandra

AU - Rodríguez-Urrego, Paula A.

AU - Matos, Leandro Luongo

AU - Mohssen, Ansarin

AU - Gheit, Tarik

AU - Tommasino, Massimo

AU - Chiocca, Susanna

AU - Villa, Luisa Lina

PY - 2022/1

Y1 - 2022/1

N2 - Background: Human papillomavirus (HPV)-driven head/neck squamous cell carcinomas (HNSCC) prevalence varies globally. We evaluated HPV DNA and p16INK4a in formalin fixed paraffin embedded (FFPE) HNSCC from Argentina, Brazil, Colombia, and Peru. Methods: HPV was genotyped by PCR-hybridization. All HPV DNA positive and some HPV DNA negative cases underwent p16INK4a immunohistochemistry. Results: HPV DNA was detected in 32.8%, 11.1%, and 17.8% of oropharyngeal (OPC), oral cavity (OCC) and laryngeal (LC) cancers, respectively. OPC HPV prevalence was higher in Colombia (94.7%), and Argentina (42.6%) compared to Brazil (10.6%) and Peru (0.0%). HPV-16 was the most detected. Other HPVs were found in LC. Higher rates of p16INK4a positivity were observed among HPV positive OPC/OCC cases compared to LC cases. Conclusions: Our results support a role for HPV-16 in a subset of HNSCC, corroborate the heterogeneity observed in samples from different countries, and contribute additional etiological and biomarkers information in tumors of significant impact worldwide.

AB - Background: Human papillomavirus (HPV)-driven head/neck squamous cell carcinomas (HNSCC) prevalence varies globally. We evaluated HPV DNA and p16INK4a in formalin fixed paraffin embedded (FFPE) HNSCC from Argentina, Brazil, Colombia, and Peru. Methods: HPV was genotyped by PCR-hybridization. All HPV DNA positive and some HPV DNA negative cases underwent p16INK4a immunohistochemistry. Results: HPV DNA was detected in 32.8%, 11.1%, and 17.8% of oropharyngeal (OPC), oral cavity (OCC) and laryngeal (LC) cancers, respectively. OPC HPV prevalence was higher in Colombia (94.7%), and Argentina (42.6%) compared to Brazil (10.6%) and Peru (0.0%). HPV-16 was the most detected. Other HPVs were found in LC. Higher rates of p16INK4a positivity were observed among HPV positive OPC/OCC cases compared to LC cases. Conclusions: Our results support a role for HPV-16 in a subset of HNSCC, corroborate the heterogeneity observed in samples from different countries, and contribute additional etiological and biomarkers information in tumors of significant impact worldwide.

KW - head and neck cancer

KW - human papillomavirus

KW - multinational study

KW - prevalence

KW - risk factors

UR - http://www.scopus.com/inward/record.url?scp=85122839302&partnerID=8YFLogxK

U2 - 10.1002/hed.26912

DO - 10.1002/hed.26912

M3 - Artículo

C2 - 34726297

AN - SCOPUS:85122839302

SN - 1043-3074

VL - 44

SP - 122

EP - 133

JO - Head and Neck Surgery

JF - Head and Neck Surgery

IS - 1

ER -